Final answer:
Insulin Glargine (rDNA origin) is used for diabetes management. It is a biotechnological product derived from recombinant DNA technology, which allows E. coli bacteria to produce human insulin, providing a critical treatment for people with type 1 diabetes.
Step-by-step explanation:
Insulin Glargine (rDNA origin) is commonly prescribed for diabetes management. Recombinant DNA (rDNA) technology has been used to produce synthetic human insulin, which is chemically identical to naturally produced insulin. This technology involves inserting the human insulin gene into bacteria, such as E. coli, which then produces insulin. This form of insulin is critical for the treatment of diabetes, specifically type 1 diabetes, where the body cannot produce insulin naturally. People with this condition require insulin from outside sources to regulate their blood glucose levels.
The production of Glargine (rDNA origin), a long-acting insulin analog, has significantly improved the quality of life for diabetics. It allows for better control of blood sugar levels with fewer injections, compared to the insulin extracted from animal sources. This advancement not only minimizes allergic reactions but also mimics the human insulin more closely, reducing the risk of immune responses.Therefore, to answer the initial question, Insulin Glargine (rDNA origin) is used in the management of diabetes, as it helps the transport and storage of glucose, thereby decreasing high blood glucose levels after meals.